<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="760">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04408170</url>
  </required_header>
  <id_info>
    <org_study_id>B00944</org_study_id>
    <nct_id>NCT04408170</nct_id>
  </id_info>
  <brief_title>Facilitating AcceLerated Clinical Validation Of Novel Diagnostics for COVID-19 (FALCON-C19)</brief_title>
  <acronym>FALCON-C19</acronym>
  <official_title>Facilitating AcceLerated Clinical Validation Of Novel Diagnostics for COVID-19 (FALCON-C19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manchester University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Manchester University NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The United Kingdom and wider world is in the midst of the 2019 novel coronavirus (SARS-CoV-2)&#xD;
      pandemic. Accurate diagnosis of infection, identification of immunity and monitoring the&#xD;
      clinical progression of infection are of paramount importance to our response. Widespread&#xD;
      population testing has proven difficult in western countries and has been limited by test&#xD;
      availability, human resources and long turnaround times (up to 72 hours). This has limited&#xD;
      our ability to control the spread of infection and to develop effective clinical pathways to&#xD;
      enable early social isolation of infected patients and early treatment for those most at&#xD;
      risk. The life sciences industry has responded to the pandemic by developing multiple new in&#xD;
      vitro diagnostic tests (IVDs). To leverage the potential clinical benefit of those tests we&#xD;
      require efficient but robust clinical evaluation. Therefore, to optimise resource utilisation&#xD;
      in this global pandemic, we will conduct a platform adaptive diagnostic study on a national&#xD;
      level, utilising a national network of expertise in the evaluation of diagnostic technology.&#xD;
      This study will enable the evaluation of multiple assays in three priority areas:&#xD;
&#xD;
        1. Evaluation of the diagnostic accuracy of IVDs for active infection with SARS-CoV-2&#xD;
&#xD;
        2. Evaluation of assays monitoring the immune response to SARS-CoV-2 infection&#xD;
&#xD;
        3. Evaluation of the prognostic value of commercially available tests for predicting&#xD;
           prognosis in patients with suspected or confirmed SARS-CoV-2 infection. (This arm will&#xD;
           not be active immediately but may be activated after initiation).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>If the participant has an active SARS-CoV-2 infection during admission</measure>
    <time_frame>Baseline</time_frame>
    <description>This will be determined using the point-of-care test and the laboratory test results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The participant has had a past SARS-CoV-2 infection</measure>
    <time_frame>Day 90</time_frame>
    <description>This will be determined using the point-of-cacre test for SARS-CoV-2 antibodies and the laboratory test results</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Coronavirus Infection</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Work Stream A</arm_group_label>
    <description>Patients that are recruited in hospital with either query COVID-19 or who have tested positive for COVID-19.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Work Stream B</arm_group_label>
    <description>Known COVID-positive and/or COVID-negative community testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Work Stream C</arm_group_label>
    <description>Undifferentiated community testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Point-of-care test for SARS-CoV-2</intervention_name>
    <description>Throat and nose swabs and/or saliva samples and/or whole blood and/or finger stick samples may be taken to be tested on Point-of-care tests for SARS-CoV-2</description>
    <arm_group_label>Work Stream A</arm_group_label>
    <arm_group_label>Work Stream B</arm_group_label>
    <arm_group_label>Work Stream C</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Throat and nose swabs and/or saliva samples may be taken at multiple time points and stored&#xD;
      for future testing.&#xD;
&#xD;
      Whole blood samples may be taken at multiple time points during the study. Samples will be&#xD;
      processed and the serum stored.&#xD;
&#xD;
      Finger stick samples may also be taken and stored for future testing.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Work Stream A: Patients who present or are referred to secondary/tertiary care settings due&#xD;
        to possible SARS-CoV-2 infection&#xD;
&#xD;
        Work Stream B: Known COVID-positive and/or COVID-negative community testing&#xD;
&#xD;
        Work Stream C: Undifferentiated community testing&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Work Stream A (in-hospital; Group 1 and Group 2):&#xD;
&#xD;
        Group 1 Inclusion Criteria:&#xD;
&#xD;
        We will include participants (patients or staff):&#xD;
&#xD;
          1. That are 18 years or older&#xD;
&#xD;
          2. That will require testing for COVID-19 in the opinion of the treating clinician&#xD;
&#xD;
          3. That may have presented with acute symptoms of COVID-19 (e.g. fever, cough, dyspnoea,&#xD;
             anosmia) or chest x-ray changes or they may be asymptomatic but require testing for&#xD;
             other reasons&#xD;
&#xD;
        Group 2 Inclusion Criteria:&#xD;
&#xD;
        We will include participants:&#xD;
&#xD;
          1. That are 18 years or older&#xD;
&#xD;
          2. That have been admitted for another reason other than suspected SARS-CoV-2 infection,&#xD;
             but when routinely swabbed they have been identified as positive for SARS-CoV-2 PCR&#xD;
&#xD;
        Work Stream B (Group 3):&#xD;
&#xD;
        We will include participants:&#xD;
&#xD;
          1. That are 18 years or older&#xD;
&#xD;
             EITHER:&#xD;
&#xD;
          2. They have been identified as positive for SARS-CoV-2 PCR through testing at national&#xD;
             laboratory infrastructure OR&#xD;
&#xD;
          3. They have been identified as negative for SARS-CoV-2 PCR through testing at national&#xD;
             laboratory infrastructure&#xD;
&#xD;
        Work Stream C (Group 4):&#xD;
&#xD;
        We will include participants:&#xD;
&#xD;
          1. That are 18 years or older&#xD;
&#xD;
          2. Who are undergoing testing for COVID-19, whether they are symptomatic or symptomatic&#xD;
             for COVID-19&#xD;
&#xD;
        Exclusion Criteria for all Work Streams:&#xD;
&#xD;
          1. Patients where it is impossible/unsafe to obtain the required research samples&#xD;
&#xD;
          2. Prisoners&#xD;
&#xD;
          3. Patients where sampling is not feasible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Richard Body</last_name>
    <role>Study Director</role>
    <affiliation>Manchester University NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elo√Øse Cook</last_name>
    <phone>0161 701 7540</phone>
    <email>FALCONstudy@mft.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sandwell General Hospital Birmingham NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central study team</last_name>
      <email>FALCONstudy@mft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Derby and Burton NHS FT</name>
      <address>
        <city>Derby</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central study team</last_name>
      <email>FALCONstudy@mft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Frimley Health NHS FT</name>
      <address>
        <city>Frimley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central study team</last_name>
      <email>FALCONstudy@mft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Airedale NHS FT</name>
      <address>
        <city>Keighley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central study team</last_name>
      <email>FALCONstudy@mft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospital NHS FT</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central study team</last_name>
      <email>FALCONstudy@mft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St George's University Hospitals NHS FT</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central study team</last_name>
      <email>FALCONstudy@mft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manchester University NHS FT</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eloise Cook</last_name>
      <phone>0161 276 3638</phone>
      <email>FALCONstudy@mft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Newcastle upon Tyne Hospitals NHS FT</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central study team</last_name>
      <email>FALCONstudy@mft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central study team</last_name>
      <email>FALCONstudy@mft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS FT</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central study team</last_name>
      <email>FALCONstudy@mft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Berkshire Hospital NHS FT</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central study team</last_name>
      <email>FALCONstudy@mft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barking, Havering &amp; Redbridge Hospitals NHS FT</name>
      <address>
        <city>Romford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central study team</last_name>
      <email>FALCONstudy@mft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS FT</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central study team</last_name>
      <email>FALCONstudy@mft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS FT</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central study team</last_name>
      <email>FALCONstudy@mft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals of North Midlands NHS Trust</name>
      <address>
        <city>Stoke-on-Trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central study team</last_name>
      <email>FALCONstudy@mft.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 26, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2020</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>In vitro diagnostics</keyword>
  <keyword>Point-of-care testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

